The study team mapped X-chromosome genetic effects on gene expression — specifically cis-expression quantitative trait loci (cis-eQTL) — across seven brain cell-types from a cohort of 423 older individuals. Investigators reported 212 X-linked genes whose expression showed evidence of genetic regulation. Many of those regulatory signals were cell-type specific rather than broadly shared across the brain cell populations profiled. Ten genes, approximately 5% of the genetically regulated set, exhibited sex-heterogeneous genetic regulation, indicating that allelic effects on expression differed between male and female samples. The source did not report experimental dosing or intervention details, as this was a genomics mapping effort rather than an interventional study.
The authors used single-nucleus RNA-seq-derived pseudobulk expression and whole-genome sequencing resources to perform the cis-eQTL mapping. Data sources named in the manuscript include ROSMAP single-nucleus RNA-seq and whole-genome sequencing datasets; summary statistics from the cell-type-specific analyses were made publicly available through the GeneXplore browser and a Zenodo repository. The paper provided no additional clinical trial identifiers because the work was observational genetic mapping, not an interventional trial.
The team also conducted sex-differential expression analyses and identified 101 sex-biased genes. Expression differences skewed toward higher female expression for the majority of these genes. The most pronounced female-upregulation was observed in microglia, where the study team observed a strong cluster of female-biased transcripts. Sex-biased expression was not uniform: it showed both shared patterns across multiple cell-types and distinct, cell-type-specific effects, with divergence most apparent in non-neuronal populations.
Investigators noted that sex-biased expression did not solely reflect the cis-eQTL findings; some transcripts showed sex-differential expression without detected cis-genetic regulation within the scope of their analyses. The authors provided summary statistics for both the cis-eQTLs and the sex-differential expression results in the supplementary materials and data repositories linked in the manuscript.
A substantial portion of the female-biased genes overlapped previously reported escape-from-X-inactivation genes, according to the authors' curated reference list. The study team observed that female-biased genes were enriched for links to Alzheimer's disease in their annotation and enrichment analyses. The authors therefore proposed that escape from X-chromosome inactivation may contribute to sex differences in neurodegenerative disease risk and molecular pathology.
The source provided curated lists of reported escape genes and used public resources (for example, GENCODE and GeneCards) for variant and gene annotation. The manuscript did not, however, claim that overlap with escape genes establishes causation; it reported enrichment and overlap as evidence suggesting a plausible mechanism for sex differences in disease biology.
To connect the cell-type genetic regulation map with disease risk, investigators integrated their resource with X-chromosome-wide association study (XWAS) summary statistics for several neurodegenerative conditions. Methods named in the manuscript included transcriptome-wide association (referred to as cTWAS in the paper), mendelian randomization, and colocalization analyses. Using these causal inference strategies, the authors nominated 11 candidate causal genes linked to specific cell-types and sex-informed mechanisms across Alzheimer's disease, Parkinson's disease, and Multiple System Atrophy.
The paper provided URLs and accession points for the XWAS summary statistics used: Alzheimer's disease summary statistics were made available via a Belloy-Lab GitHub repository; Parkinson's and other disease XWAS datasets were drawn from the GWAS Catalog entries cited in the manuscript. Investigators reported candidate-gene nominations as outputs of integrated analyses rather than validated therapeutic targets; the source did not report experimental validation or functional follow-up experiments within this preprint.
All cell-type-specific X-chromosome cis and trans-eQTL summary statistics generated in this work are available through the GeneXplore browser and a Zenodo repository, according to the manuscript. The authors also cited public reference resources used for annotation including gnomAD v3.1.1 and GENCODE v48.
This article is a preprint and has not been certified by peer review; the authors and the hosting repository explicitly state that the findings should not be used to guide clinical practice. The manuscript reported institutional ethical approval (Institutional Review Board of Rush University Medical Center) and provided data-access instructions, but it did not present interventional data, clinical trial endpoints, or regulatory milestones. The study therefore leaves several specific questions open: which nominated genes will validate in independent cohorts; which molecular mechanisms mediate the sex-heterogeneous genetic effects; and whether functional perturbation of nominated genes alters neurodegenerative phenotypes. Those questions were not answered in the preprint and will require additional experimental and replication work before translational or regulatory steps can be pursued.